Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Slides:

Advertisements

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Advertisements

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

JAK2 knockdown abrogates tumorsphere expansion after chemotherapy

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Colonization in tumor models and different modes of administration

Protection from 4T1 tumor rechallenge in treated mice.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

Antitumor immunity caused by DS-8201a.

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

SPARC is required for spontaneous metastasis

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

BV6 increases bone metastasis.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Ex vivo profiling of PD-1 blockade using MDOTS

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Presentation transcript:

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. (A and B) Effect of M7824 on tumor growth. Tumor volume (in cubic millimeters) of Jh mice (n = 12 to 13 per treatment) (A) orthotopically inoculated with 0.25 × 106 EMT-6 cells (day −7) and μMt− mice (n = 8 per treatment) (B) intramuscularly inoculated with 0.5 × 106 MC38 cells (day −7) and treated intravenously with isotype control (133 or 400 μg), trap control (164 μg), anti–PD-L1 (133 or 400 μg), M7824 (164 or 492 μg), or trap control (164 μg) + anti–PD-L1 (133 μg) three times a week for 2 weeks (A) or on days 0 and 2 (B). Means ± SEM are shown. (C and D) Number of tumor nodules in the lungs (C) and incidence of metastases in BALB/c mice (D) orthotopically injected with 0.25 × 106 EMT-6 cells (day −7) and treated (n = 21 per group) with a single dose of isotype control (400 μg), trap control (492 μg), anti–PD-L1 (400 μg), or M7824 (492 μg). The mice were sacrificed when isotype control mice reached 1000-mm3 tumor volume. Data from individual mice and means are shown; P values by unpaired t test. (E and F) Percent surviving mice and tumor rechallenge; mice were sacrificed when tumor volume reached ≈2500 mm3. (E) Percent surviving Jh mice orthotopically injected in the right mammary pad with 0.25 × 106 EMT-6 cells (day −7) and treated (n = 9 mice per group) with M7824 (492 μg; days 0 and 14) or isotype control (133 μg; days 0, 7, and 14). For rechallenge, M7824-cured (n = 9) or treatment-naive mice (n = 10) were subcutaneously injected with 0.25 × 105 EMT-6 cells (218 days after final treatment). Tumor volume was measured twice weekly. (F) Percent surviving μMt− mice intramuscularly injected with 0.5 × 106 MC38 cells (day −7) and treated (n = 10 mice per group) with M7824 (492 μg) or isotype control (400 μg) on days 0, 2, 4, 7, 9, and 11. M7824-cured or treatment-naive mice (n = 8 and 10, respectively) were subcutaneously injected with 0.1 × 106 MC38 cells (77 days after final treatment). Tumor volume was measured on days 7, 10, 14, and 18. Means ± SEM are shown. *P ≤ 0.05 and ****P ≤ 0.0001 denote a significant difference relative to an equimolar dose of M7824. Yan Lan et al., Sci Transl Med 2018;10:eaan5488 Published by AAAS